As of mid-2026, retatrutide has cleared its first pivotal phase 3 hurdle. The TRIUMPH-1 trial showed roughly 28.3% average weight loss at 80 weeks, the largest of any obesity drug in late-stage testing. But it is not yet FDA-approved, and the diabetes and cardiovascular trials are still pending.
What is retatrutide, exactly?
Retatrutide (development code LY3437943) is an investigational once-weekly injectable from Eli Lilly. It is a triple agonist: it activates the receptors for GLP-1, GIP, and glucagon at once. GLP-1 and GIP are the two incretin pathways already used by tirzepatide; glucagon is the third lever, added to increase energy expenditure and liver fat burning. Our explainer on how the retatrutide triple agonist works covers the receptor balance in detail.
What did the phase 2 trial prove?
The phase 2 obesity trial, published in the New England Journal of Medicine in 2023, enrolled 338 adults with obesity and ran for 48 weeks. At the top 12 mg dose, participants lost an average of 24.2% of body weight, the largest figure reported for an obesity drug at that time. Crucially, the weight-loss curve had not clearly plateaued by 48 weeks, suggesting more was possible with longer treatment, which is part of why the phase 3 program drew so much attention.
What did TRIUMPH-1 show in 2026?
Eli Lilly reported topline TRIUMPH-1 results in May 2026. The trial enrolled 2,339 adults with obesity or overweight plus at least one weight-related condition, but without type 2 diabetes, and ran 80 weeks.
| Endpoint | Result |
|---|---|
| Mean weight loss, 12 mg, 80 wk | 28.3% (about 70 lb) |
| Participants losing 30%+ | ~45% |
| BMI 35+ subgroup continuing to 104 wk | up to 30.3% (about 85 lb) |
| Doses meeting primary endpoint | 4 mg, 9 mg, and 12 mg |
All three tested doses beat placebo on the primary and key secondary endpoints. The 30%-loss threshold is notable because it edges into territory previously associated mainly with bariatric surgery. Detailed results were slated for presentation at major 2026 scientific meetings with peer-reviewed publication to follow. For more on the trial structure, see reading the TRIUMPH trial data.
What is still pending?
TRIUMPH-1 is one trial in obesity without diabetes. The wider program is not finished:
- TRIUMPH-2 tests retatrutide in adults with obesity or overweight and type 2 diabetes.
- TRIUMPH-3 studies adults with established cardiovascular disease, the trial that matters most for proving outcome benefits, not just weight.
- Additional studies cover related conditions such as osteoarthritis-associated outcomes.
Until those read out and the FDA reviews the full package, retatrutide remains investigational. Our tracker on when retatrutide will be available follows the timeline as it firms up.
TRIUMPH-3 deserves particular attention because cardiovascular outcome trials are what separate a weight-loss drug from a drug that demonstrably reduces heart attacks, strokes, and deaths. Semaglutide earned that kind of label expansion only after a dedicated outcomes trial, and tirzepatide's outcome data are still maturing. Retatrutide producing large weight loss does not automatically prove it improves cardiovascular outcomes, even though weight loss usually moves risk factors in the right direction. Likewise, TRIUMPH-2 will show whether the triple agonist holds its advantage in people with type 2 diabetes, where GLP-1 drugs sometimes produce somewhat less weight loss than in people without diabetes. Those answers, not the obesity headline alone, will shape how broadly retatrutide is eventually used.
What do we know about side effects?
The side-effect profile so far matches the GLP-1 class: gastrointestinal symptoms, nausea, vomiting, diarrhea, dominate and concentrate during dose escalation. Retatrutide also produces a modest increase in heart rate, attributed partly to its glucagon activity. The phase 2 data showed these effects were generally dose-dependent and most prominent while titrating up. The full safety picture, especially long-term, depends on the larger phase 3 dataset. See retatrutide side effects for the current detail.
What about body composition and liver fat?
Two signals beyond the scale have drawn interest. First, a separate phase 2a trial reported substantial reductions in liver fat in people with metabolic dysfunction-associated steatotic liver disease, with many achieving normal liver-fat levels. Second, body-composition analyses suggest a meaningful share of weight lost is fat rather than lean mass, though protecting muscle still requires adequate protein and resistance training. These are promising but earlier-stage findings than the headline weight numbers.
The liver-fat result is worth watching because fatty liver disease is common in obesity and currently has few effective drug treatments, so a weight-loss agent that also clears liver fat could matter beyond the scale. The glucagon component is the likely driver here, since glucagon signaling pushes the liver to mobilize and burn stored fat. Still, a phase 2a trial is a small, early look; confirming that benefit and tying it to hard outcomes like reduced progression to cirrhosis would take dedicated, larger studies that have not yet reported.
When could retatrutide actually be approved?
There is no confirmed approval date. With TRIUMPH-1 positive in 2026 but the diabetes and cardiovascular trials still running, a realistic expectation is that a regulatory filing and decision follow once that data matures, plausibly into 2027 or beyond. Anyone claiming to sell approved retatrutide today is mistaken or misleading; legitimate access is currently limited to clinical trials.
What is proven versus still hype?
Proven: retatrutide produces very large weight loss in obesity over 80 weeks, with a class-typical side-effect profile. Not yet proven: cardiovascular outcome benefits, long-term safety, performance in diabetes, and real-world durability after stopping. The numbers are genuinely impressive, but "impressive trial result" is not the same as "approved, available, and proven safe over years."
References
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial. New England Journal of Medicine, 2023. https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
- Eli Lilly. Retatrutide delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1), May 2026. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss
- Sanyal AJ, et al. Triple hormone-receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine, 2024. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11271400/
Frequently Asked Questions
Is retatrutide FDA-approved in 2026?
No. As of mid-2026 it has positive phase 3 data from TRIUMPH-1 but remains investigational, with diabetes and cardiovascular trials still in progress and no FDA approval.
How much weight did retatrutide cause in trials?
About 24.2% at 48 weeks in phase 2 and roughly 28.3% at 80 weeks in the phase 3 TRIUMPH-1 trial at the top dose, with around 45% of participants losing at least 30% of body weight.
Can I buy retatrutide legally right now?
Legitimate access is limited to clinical trials. Products sold online as retatrutide are unregulated and not the FDA-reviewed drug, so purity and dosing cannot be verified.
When will retatrutide be available?
No date is confirmed. Approval depends on the remaining phase 3 trials and FDA review, which realistically points beyond 2026.
This article is educational and not medical advice; treatment decisions should be made with a licensed clinician.
